Multifunctional Cargo-Free Nanomedicine for Cancer Therapy
Abstract
:1. Introduction
2. Classification of Cargo-Free Nanomedicine
2.1. Drug Nanocrystals
2.2. Prodrug Self-Assembly Nanoparticles
2.3. Drug–Drug Conjugate Nanoparticles
2.4. ADCs
3. Representative Applications of Cargo-Free Nanomedicine
3.1. Chemo–Chemotherapeutics Combination Therapy
3.2. Chemo–Photosensitizer Combination Therapy
3.2.1. Chemo–Photodynamic Combination Therapy
3.2.2. Chemo–Photothermal Combination Therapy
3.3. Other Applications
3.3.1. Immunotherapy
3.3.2. Real-Time Self-Monitoring of Drug Release
4. Challenges and Future Perspectives of Cargo-Free Nanomedicine
Author Contributions
Funding
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Ke, H.; Dai, Z.; Liu, Z. Nanoscale theranostics for physical stimulus-responsive cancer therapies. Biomaterials 2015, 73, 214–230. [Google Scholar] [CrossRef] [PubMed]
- Zhao, C.-Y.; Cheng, R.; Yang, Z.; Tian, Z.-M. Nanotechnology for cancer therapy based on chemotherapy. Molecules 2018, 23, 826. [Google Scholar] [CrossRef] [PubMed]
- Wu, Q.; Yang, Z.; Nie, Y.; Shi, Y.; Fan, D. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 2014, 347, 159–166. [Google Scholar] [CrossRef] [PubMed]
- Perez-Herrero, E.; Fernandez-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 2015, 93, 52–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dong, X.; Mumper, R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. Nanomedicine 2010, 5, 597–615. [Google Scholar] [CrossRef] [PubMed]
- Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Sun, S.; Zhang, Z.; Shi, D. Nanomaterials for cancer precision medicine. Adv. Mater. 2018, 30, e1705660. [Google Scholar] [CrossRef] [PubMed]
- Barenholz, Y.C. Doxil®—The first fda-approved nano-drug: Lessons learned. J. Control. Release 2012, 160, 117–134. [Google Scholar] [CrossRef] [PubMed]
- Sofias, A.M.; Dunne, M.; Storm, G.; Allen, C. The battle of “nano” paclitaxel. Adv. Drug Deliv. Rev. 2017, 122, 20–30. [Google Scholar] [CrossRef] [PubMed]
- Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release 2016, 244, 108–121. [Google Scholar] [CrossRef] [PubMed]
- Sun, Q.; Radosz, M.; Shen, Y. Challenges in design of translational nanocarriers. J. Control. Release 2012, 164, 156–169. [Google Scholar] [CrossRef] [PubMed]
- Hu, S.; Lee, E.; Wang, C.; Wang, J.; Zhou, Z.; Li, Y.; Li, X.; Tang, J.; Lee, D.H.; Liu, X. Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy. J. Control. Release 2015, 220, 175–179. [Google Scholar] [CrossRef] [PubMed]
- Mou, Q.; Ma, Y.; Zhu, X.; Yan, D. A small molecule nanodrug consisting of amphiphilic targeting ligand–chemotherapy drug conjugate for targeted cancer therapy. J. Control. Release 2016, 230, 34–44. [Google Scholar] [CrossRef] [PubMed]
- De Jong, W.H.; Borm, P.J. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomed. 2008, 3, 133–149. [Google Scholar] [CrossRef]
- Franz, S.; Rammelt, S.; Scharnweber, D.; Simon, J.C. Immune responses to implants–a review of the implications for the design of immunomodulatory biomaterials. Biomaterials 2011, 32, 6692–6709. [Google Scholar] [CrossRef] [PubMed]
- Athanasiou, K.A.; Niederauer, G.G.; Agrawal, C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996, 17, 93–102. [Google Scholar] [CrossRef]
- Meinel, L.; Hofmann, S.; Karageorgiou, V.; Kirker-Head, C.; McCool, J.; Gronowicz, G.; Zichner, L.; Langer, R.; Vunjak-Novakovic, G.; Kaplan, D.L. The inflammatory responses to silk films in vitro and in vivo. Biomaterials 2005, 26, 147–155. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Zhao, Q.; Han, N.; Bai, L.; Li, J.; Liu, J.; Che, E.; Hu, L.; Zhang, Q.; Jiang, T. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomed. Nanotechnol. 2015, 11, 313–327. [Google Scholar] [CrossRef] [PubMed]
- Yang, P.; Gai, S.; Lin, J. Functionalized mesoporous silica materials for controlled drug delivery. Chem. Soc. Rev. 2012, 41, 3679–3698. [Google Scholar] [CrossRef] [PubMed]
- Qin, S.-Y.; Zhang, A.-Q.; Cheng, S.-X.; Rong, L.; Zhang, X.-Z. Drug self-delivery systems for cancer therapy. Biomaterials 2017, 112, 234–247. [Google Scholar] [CrossRef] [PubMed]
- Ma, W.; Cheetham, A.G.; Cui, H. Building nanostructures with drugs. Nano Today 2016, 11, 13–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jia, J.; Zhu, F.; Ma, X.; Cao, Z.W.; Li, Y.X.; Chen, Y.Z. Mechanisms of drug combinations: Interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8, 111. [Google Scholar] [CrossRef] [PubMed]
- Ma, Y.; Mou, Q.; Zhu, X.; Yan, D. Small molecule nanodrugs for cancer therapy. Mater. Today Chem. 2017, 4, 26–39. [Google Scholar] [CrossRef]
- Möschwitzer, J.P. Drug nanocrystals in the commercial pharmaceutical development process. Int. J. Pharm. 2013, 453, 142–156. [Google Scholar] [CrossRef] [PubMed]
- Gao, L.; Zhang, D.; Chen, M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 2008, 10, 845–862. [Google Scholar] [CrossRef]
- Guo, S.; Huang, L. Nanoparticles containing insoluble drug for cancer therapy. Biotechnol. Adv. 2014, 32, 778–788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miao, X.; Yang, W.; Feng, T.; Lin, J.; Huang, P. Drug nanocrystals for cancer therapy. Wires. Nanomed. Nanobiotechnol. 2018, 10, e1499. [Google Scholar] [CrossRef] [PubMed]
- Keck, C.M.; Müller, R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62, 3–16. [Google Scholar] [CrossRef] [PubMed]
- Juhnke, M.; Märtin, D.; John, E. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur. J. Pharm. Biopharm. 2012, 81, 214–222. [Google Scholar] [CrossRef] [PubMed]
- Chan, H.-K.; Kwok, P.C.L. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63, 406–416. [Google Scholar] [CrossRef] [PubMed]
- Van Eerdenbrugh, B.; Van den Mooter, G.; Augustijns, P. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 2008, 364, 64–75. [Google Scholar] [CrossRef] [PubMed]
- Rabinow, B.E.; Gupta, P.; Wong, J.; Papadopoulos, P.; Chaubal, M. Formulation of water-insoluble antineoplastic agents as nanosuspensions using nanoedge formulation technology. Cancer Res. 2004, 64, 146. [Google Scholar]
- Salazar, J.; Müller, R.H.; Möschwitzer, J.P. Combinative particle size reduction technologies for the production of drug nanocrystals. J. Pharm. 2014, 2014, 265754. [Google Scholar] [CrossRef] [PubMed]
- Van Eerdenbrugh, B.; Froyen, L.; Van Humbeeck, J.; Martens, J.A.; Augustijns, P.; Van den Mooter, G. Drying of crystalline drug nanosuspensions—The importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur. J. Pharm. Sci. 2008, 35, 127–135. [Google Scholar] [CrossRef] [PubMed]
- Kulke, M.H.; Chan, J.A.; Meyerhardt, J.A.; Zhu, A.X.; Abrams, T.A.; Blaszkowsky, L.S.; Regan, E.; Sidor, C.; Fuchs, C.S. A prospective phase ii study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemoth. Pharm. 2011, 68, 293–300. [Google Scholar] [CrossRef] [PubMed]
- Chen, F.; Zhao, Y.; Pan, Y.; Xue, X.; Zhang, X.; Kumar, A.; Liang, X.-J. Synergistically enhanced therapeutic effect of a carrier-free hcpt/dox nanodrug on breast cancer cells through improved cellular drug accumulation. Mol. Pharm. 2015, 12, 2237–2244. [Google Scholar] [CrossRef] [PubMed]
- Pastorino, F.; Loi, M.; Sapra, P.; Becherini, P.; Cilli, M.; Emionite, L.; Ribatti, D.; Greenberger, L.M.; Horak, I.D.; Ponzoni, M. Tumor regression and curability of preclinical neuroblastoma models by pegylated sn38 (ezn-2208), a novel topoisomerase Ι inhibitor. Clin. Cancer Res. 2010, 16, 4809–4821. [Google Scholar] [CrossRef] [PubMed]
- Koseki, Y.; Ikuta, Y.; Kamishima, T.; Onodera, T.; Oikawa, H.; Kasai, H. Drug release is determined by the chain length of fatty acid-conjugated anticancer agent as one component of nano-prodrug. Bull. Chem. Soc. JPN 2016, 89, 540–545. [Google Scholar] [CrossRef]
- Yao, Q.; Kou, L.; Tu, Y.; Zhu, L. Mmp-responsive ‘smart’ drug delivery and tumor targeting. Trends Pharmacol. Sci. 2018, 39, 766–781. [Google Scholar] [CrossRef] [PubMed]
- Sun, D.; Ding, J.; Xiao, C.; Chen, J.; Zhuang, X.; Chen, X. Preclinical evaluation of antitumor activity of acid-sensitive pegylated doxorubicin. ACS Appl. Mater. Interfaces 2014, 6, 21202–21214. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Q.; Ko, N.R.; Oh, J.K. Recent advances in stimuli-responsive degradable block copolymer micelles: Synthesis and controlled drug delivery applications. Chem. Commun. 2012, 48, 7542–7552. [Google Scholar] [CrossRef] [PubMed]
- Torchilin, V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13, 813–827. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161–174. [Google Scholar] [CrossRef] [PubMed]
- Sun, Z.; Li, R.; Sun, J.; Peng, Y.; Xiao, L.; Zhang, X.; Xu, Y.; Wang, M. Matrix metalloproteinase cleavable nanoparticles for tumor microenvironment and tumor cell dual-targeting drug delivery. ACS Appl. Mater. Interfaces 2017, 9, 40614–40627. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, A.; Fukuoka, Y.; Morimoto, Y.; Honjo, T.; Koda, D.; Goto, M.; Maruyama, T. Cancer cell death induced by the intracellular self-assembly of an enzyme-responsive supramolecular gelator. J. Am. Chem. Soc. 2015, 137, 770–775. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Wang, J.; Mao, W.; Huang, J.; Wu, X.; Shen, Y.; Sui, M. Novel sn38 conjugate-forming nanoparticles as anticancer prodrug: In vitro and in vivo studies. J. Control. Release 2013, 166, 147–158. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Cheetham, A.G.; Angacian, G.; Su, H.; Xie, L.; Cui, H. Peptide–drug conjugates as effective prodrug strategies for targeted delivery. Adv. Drug Deliv. Rev. 2017, 110, 112–126. [Google Scholar] [CrossRef] [PubMed]
- Yang, Z.; Luo, X.; Zhang, X.; Liu, J.; Jiang, Q. Targeted delivery of 10-hydroxycamptothecin to human breast cancers by cyclic rgd-modified lipid–polymer hybrid nanoparticles. Biomed. Mater. 2013, 8, 025012. [Google Scholar] [CrossRef] [PubMed]
- Peng, M.; Qin, S.; Jia, H.; Zheng, D.; Rong, L.; Zhang, X. Self-delivery of a peptide-based prodrug for tumor-targeting therapy. Nano Res. 2016, 9, 663–673. [Google Scholar] [CrossRef]
- Huang, P.; Wang, D.; Su, Y.; Huang, W.; Zhou, Y.; Cui, D.; Zhu, X.; Yan, D. Combination of small molecule prodrug and nanodrug delivery: Amphiphilic drug–drug conjugate for cancer therapy. J. Am. Chem. Soc. 2014, 136, 11748–11756. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Deng, H.; Huang, P.; Sun, P.; Huang, X.; Su, Y.; Zhu, X.; Shen, J.; Yan, D. Real-time self-tracking of an anticancer small molecule nanodrug based on colorful fluorescence variations. RSC Adv. 2016, 6, 12472–12478. [Google Scholar] [CrossRef]
- Zhang, T.; Huang, P.; Shi, L.; Su, Y.; Zhou, L.; Zhu, X.; Yan, D. Self-assembled nanoparticles of amphiphilic twin drug from floxuridine and bendamustine for cancer therapy. Mol. Pharm. 2015, 12, 2328–2336. [Google Scholar] [CrossRef] [PubMed]
- Hu, M.; Huang, P.; Wang, Y.; Su, Y.; Zhou, L.; Zhu, X.; Yan, D. Synergistic combination chemotherapy of camptothecin and floxuridine through self-assembly of amphiphilic drug–drug conjugate. Bioconjug. Chem. 2015, 26, 2497–2506. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.; Zhu, G.; Jacobson, O.; Liu, Y.; Chen, K.; Yu, G.; Ni, Q.; Fan, J.; Yang, Z.; Xu, F. Transformative nanomedicine of an amphiphilic camptothecin prodrug for long circulation and high tumor uptake in cancer therapy. ACS Nano 2017, 11, 8838–8848. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Yu, C.; Xu, L.; Shi, L.; Tong, G.; Wu, J.; Liu, H.; Yan, D.; Zhu, X. Nucleoside analogue-based supramolecular nanodrugs driven by molecular recognition for synergistic cancer therapy. J. Am. Chem. Soc. 2018, 140, 8797–8806. [Google Scholar] [CrossRef] [PubMed]
- Cong, Y.; Xiao, H.; Xiong, H.; Wang, Z.; Ding, J.; Li, C.; Chen, X.; Liang, X.J.; Zhou, D.; Huang, Y. Dual drug backboned shattering polymeric theranostic nanomedicine for synergistic eradication of patient-derived lung cancer. Adv. Mater. 2018, 30, 1706220. [Google Scholar] [CrossRef] [PubMed]
- Teicher, B.A.; Chari, R.V.J. Antibody conjugate therapeutics: Challenges and potential. Clin. Cancer Res. 2011, 17, 6389–6397. [Google Scholar] [CrossRef] [PubMed]
- Nasiri, H.; Valedkarimi, Z.; Aghebati-Maleki, L.; Majidi, J. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy. J. Cell Physiol. 2018, 233, 6441–6457. [Google Scholar] [CrossRef] [PubMed]
- Tsimberidou, A.-M.; Giles, F.J.; Estey, E.; O’Brien, S.; Keating, M.J.; Kantarjian, H.M. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br. J. Haematol. 2006, 132, 398–409. [Google Scholar] [CrossRef] [PubMed]
- Petersdorf, S.H.; Kopecky, K.J.; Slovak, M.; Willman, C.; Nevill, T.; Brandwein, J.; Larson, R.A.; Erba, H.P.; Stiff, P.J.; Stuart, R.K.; et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121, 4854–4860. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- LoRusso, P.M.; Weiss, D.; Guardino, E.; Girish, S.; Sliwkowski, M.X. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2–positive cancer. Clin. Cancer Res. 2011, 17, 6437. [Google Scholar] [CrossRef] [PubMed]
- Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.-Y.; Diéras, V.; Guardino, E.; et al. Trastuzumab emtansine for her2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367, 1783–1791. [Google Scholar] [CrossRef] [PubMed]
- Kung Sutherland, M.S.; Walter, R.B.; Jeffrey, S.C.; Burke, P.J.; Yu, C.; Kostner, H.; Stone, I.; Ryan, M.C.; Sussman, D.; Lyon, R.P.; et al. Sgn-cd33a: A novel cd33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant aml. Blood 2013, 122, 1455. [Google Scholar] [CrossRef] [PubMed]
- Kennedy, D.A.; Alley, S.C.; Zhao, B.; Feldman, E.J.; O’Meara, M.; Sutherland, M. Abstract ddt02-04: Sgn-cd33a: Preclinical and phase 1 interim clinical trial results of a cd33-directed pbd dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML). Cancer Res. 2015, 75. [Google Scholar] [CrossRef]
- Rudin, C.M.; Pietanza, M.C.; Bauer, T.M.; Ready, N.; Morgensztern, D.; Glisson, B.S.; Byers, L.A.; Johnson, M.L.; Burris, H.A.; Robert, F.; et al. Rovalpituzumab tesirine, a dll3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017, 18, 42–51. [Google Scholar] [CrossRef]
- Hamblett, K.J.; Hammond, P.W.; Barnscher, S.D.; Fung, V.K.; Davies, R.H.; Wickman, G.R.; Hernandez, A.; Ding, T.; Galey, A.S.; Winters, G.C.; et al. Abstract 3914: Zw49, a her2-targeted biparatopic antibody-drug conjugate for the treatment of her2-expressing cancers. Cancer Res. 2018, 78, 3914. [Google Scholar] [CrossRef]
- Koopman, L.A.; Janmaat, M.L.; Jacobsen, K.; Terp, M.G.; Heuvel, E.G.-V.D.; Forssman, U.; Lingnau, A.; Parren, P.W.; Ditzel, H.; Breij, E.C. Abstract 832: An axl-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including egfr-inhibitor resistant nsclc. Cancer Res. 2018, 78, 832. [Google Scholar] [CrossRef]
- Marusyk, A.; Almendro, V.; Polyak, K. Intra-tumour heterogeneity: A looking glass for cancer? Nat. Rev. Cancer 2012, 12, 323–334. [Google Scholar] [CrossRef] [PubMed]
- Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug Resistance in Cancer: An Overview. Cancers 2014, 6, 1769–1792. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, S.C.; Yang, X.R.; Lu, Y.; Fan, Z.X.; Li, Y.; Jiang, Y.; Hou, Z.Q. A green approach to dual-drug nanoformulations with targeting and synergistic effects for cancer therapy. Drug Deliv. 2017, 24, 51–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, M.; Zhang, X.; Yang, Y.; Liu, Z.; Tian, B.; Jie, J.; Zhang, X. Carrier-free functionalized multidrug nanorods for synergistic cancer therapy. Biomaterials 2013, 34, 8960–8967. [Google Scholar] [CrossRef] [PubMed]
- Meacham, C.E.; Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501, 328–337. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, Z.; Sun, N.; Cheng, R.; Zhao, C.; Liu, Z.; Li, X.; Liu, J.; Tian, Z. Ph multistage responsive micellar system with charge-switch and peg layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. Biomaterials 2017, 147, 53–67. [Google Scholar] [CrossRef] [PubMed]
- Yang, Z.; Sun, N.; Cheng, R.; Zhao, C.; Liu, J.; Tian, Z. Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. J. Mater. Chem. B 2017, 5, 6762–6775. [Google Scholar] [CrossRef]
- Sun, N.; Zhao, C.; Cheng, R.; Liu, Z.; Li, X.; Lu, A.; Tian, Z.; Yang, Z. Cargo-free nanomedicine with ph-sensitivity for co-delivery of dox conjugated prodrug with sn38 to synergistically eradicate breast cancer stem cells. Mol. Pharm. 2018, 15, 3343–3355. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Agarwal, P.; Zhao, S.; Xu, R.X.; Yu, J.; Lu, X.; He, X. Hyaluronic acid-decorated dual responsive nanoparticles of pluronic f127, plga, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 2015, 72, 74–89. [Google Scholar] [CrossRef] [PubMed]
- Castano, A.P.; Mroz, P.; Hamblin, M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6, 535–545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moan, J.; Peng, Q. An outline of the hundred-year history of pdt. Anticancer Res. 2003, 23, 3591–3600. [Google Scholar] [PubMed]
- Ji, C.; Gao, Q.; Dong, X.; Yin, W.; Gu, Z.; Gan, Z.; Zhao, Y.; Yin, M. Size-reducible nanodrug with aggregation-enhanced photodynamic effect for deep chemo-photodynamic therapy. Angew. Chem. Int. Ed. 2018. [Google Scholar] [CrossRef]
- Tian, G.; Zhang, X.; Gu, Z.; Zhao, Y. Recent advances in upconversion nanoparticles-based multifunctional nanocomposites for combined cancer therapy. Adv. Mater. 2015, 27, 7692–7712. [Google Scholar] [CrossRef] [PubMed]
- Wen, Y.; Zhang, W.; Gong, N.; Wang, Y.-F.; Guo, H.-B.; Guo, W.; Wang, P.C.; Liang, X.-J. Carrier-free, self-assembled pure drug nanorods composed of 10-hydroxycamptothecin and chlorin e6 for combinatorial chemo-photodynamic antitumor therapy in vivo. Nanoscale 2017, 9, 14347–14356. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Yu, S.; Lee, D.; Kim, G.; Lee, B.; Cho, Y.; Zheng, B.-Y.; Ke, M.-R.; Huang, J.-D.; Nam, K.T. Facile supramolecular approach to nucleic-acid-driven activatable nanotheranostics that overcome drawbacks of photodynamic therapy. ACS Nano 2017, 12, 681–688. [Google Scholar] [CrossRef] [PubMed]
- Yang, Z.; Cheng, R.; Zhao, C.; Sun, N.; Luo, H.; Chen, Y.; Liu, Z.; Li, X.; Liu, J.; Tian, Z. Thermo-and ph-dual responsive polymeric micelles with upper critical solution temperature behavior for photoacoustic imaging-guided synergistic chemo-photothermal therapy against subcutaneous and metastatic breast tumors. Theranostics 2018, 8, 4097–4115. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.; Wang, H.; Chen, Y.; Wang, Y.; Li, H.; Han, H.; Chen, T.; Jin, Q.; Ji, J. Ph-and nir light-responsive polymeric prodrug micelles for hyperthermia-assisted site-specific chemotherapy to reverse drug resistance in cancer treatment. Small 2016, 12, 2731–2740. [Google Scholar] [CrossRef] [PubMed]
- Yang, K.; Feng, L.; Shi, X.; Liu, Z. Nano-graphene in biomedicine: Theranostic applications. Chem. Soc. Rev. 2013, 42, 530–547. [Google Scholar] [CrossRef] [PubMed]
- Terentyuk, G.; Panfilova, E.; Khanadeev, V.; Chumakov, D.; Genina, E.; Bashkatov, A.; Tuchin, V.; Bucharskaya, A.; Maslyakova, G.; Khlebtsov, N. Gold nanorods with a hematoporphyrin-loaded silica shell for dual-modality photodynamic and photothermal treatment of tumors in vivo. Nano Res. 2014, 7, 325–337. [Google Scholar] [CrossRef]
- Tian, Q.; Tang, M.; Sun, Y.; Zou, R.; Chen, Z.; Zhu, M.; Yang, S.; Wang, J.; Wang, J.; Hu, J. Hydrophilic flower-like cus superstructures as an efficient 980 nm laser-driven photothermal agent for ablation of cancer cells. Adv. Mater. 2011, 23, 3542–3547. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Tang, S.; Mu, X.; Dai, Y.; Chen, G.; Zhou, Z.; Ruan, F.; Yang, Z.; Zheng, N. Freestanding palladium nanosheets with plasmonic and catalytic properties. Nat. Nanotechnol. 2011, 6, 28–32. [Google Scholar] [CrossRef] [PubMed]
- Chou, S.S.; Kaehr, B.; Kim, J.; Foley, B.M.; De, M.; Hopkins, P.E.; Huang, J.; Brinker, C.J.; Dravid, V.P. Chemically exfoliated mos2 as near-infrared photothermal agents. Angew. Chem. Int. Ed. 2013, 125, 4254–4258. [Google Scholar] [CrossRef]
- Kobayashi, H.; Ogawa, M.; Alford, R.; Choyke, P.L.; Urano, Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem. Rev. 2009, 110, 2620–2640. [Google Scholar] [CrossRef] [PubMed]
- Zheng, M.; Yue, C.; Ma, Y.; Gong, P.; Zhao, P.; Zheng, C.; Sheng, Z.; Zhang, P.; Wang, Z.; Cai, L. Single-step assembly of dox/icg loaded lipid–polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano 2013, 7, 2056–2067. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Liu, G.; Ma, J.; Lin, J.; Lin, H.; Su, G.; Chen, D.; Ye, S.; Chen, X.; Zhu, X. Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy. J. Control. Release 2017, 258, 95–107. [Google Scholar] [CrossRef] [PubMed]
- Zhao, R.; Zheng, G.; Fan, L.; Shen, Z.; Jiang, K.; Guo, Y.; Shao, J.-W. Carrier-free nanodrug by co-assembly of chemotherapeutic agent and photosensitizer for cancer imaging and chemo-photo combination therapy. Acta Biomater. 2018, 70, 197–210. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Liu, S.; Hu, X.; Xie, Z.; Jing, X. Cyanine-curcumin assembling nanoparticles for near-infrared imaging and photothermal therapy. ACS Biomater. Sci. Eng. 2016, 2, 1942–1950. [Google Scholar] [CrossRef]
- Galluzzi, L.; Buque, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer cell 2015, 28, 690–714. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.A.; Minn, A.J. Combination cancer therapy with immune checkpoint blockade: Mechanisms and strategies. Immunity 2018, 48, 417–433. [Google Scholar] [CrossRef] [PubMed]
- Sharma, P.; Allison, J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015, 161, 205–214. [Google Scholar] [CrossRef] [PubMed]
- Luo, L.; Shu, R.; Wu, A. Nanomaterial-based cancer immunotherapy. J. Mater. Chem. B 2017, 5, 5517–5531. [Google Scholar] [CrossRef]
- Fan, Q.; Chen, Z.; Wang, C.; Liu, Z. Toward biomaterials for enhancing immune checkpoint blockade therapy. Adv. Funct. Mater. 2018. [Google Scholar] [CrossRef]
- Yang, R.; Xu, J.; Xu, L.; Sun, X.; Chen, Q.; Zhao, Y.; Peng, R.; Liu, Z. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano 2018, 12, 5121–5129. [Google Scholar] [CrossRef] [PubMed]
- Luo, L.; Zhu, C.; Yin, H.; Jiang, M.; Zhang, J.; Qin, B.; Luo, Z.; Yuan, X.; Yang, J.; Li, W. Laser immunotherapy in combination with perdurable pd-1 blocking for treatment of metastatic tumor. ACS Nano 2018. [Google Scholar] [CrossRef] [PubMed]
- Boushehri, M.A.S.; Stein, V.; Lamprecht, A. Cargo-free particles of ammonio methacrylate copolymers: From pharmaceutical inactive ingredients to effective anticancer immunotherapeutics. Biomaterials 2018, 166, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Fan, L.; Zhang, B.; Xu, A.; Shen, Z.; Guo, Y.; Zhao, R.; Yao, H.; Shao, J.W. Carrier-free, pure nanodrug formed by the self-assembly of an anticancer drug for cancer immune therapy. Mol. Pharm. 2018, 15, 2466–2478. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Li, S.; An, F.-F.; Liu, J.; Jin, S.; Zhang, J.-C.; Wang, P.C.; Zhang, X.; Lee, C.-S.; Liang, X.-J. Self-carried curcumin nanoparticles for in vitro and in vivo cancer therapy with real-time monitoring of drug release. Nanoscale 2015, 7, 13503–13510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, J.; Liang, Y.-C.; Lin, X.; Zhu, X.; Yan, L.; Li, S.; Yang, X.; Zhu, G.; Rogach, A.L.; Yu, P.K. Self-monitoring and self-delivery of photosensitizer-doped nanoparticles for highly effective combination cancer therapy in vitro and in vivo. ACS Nano 2015, 9, 9741–9756. [Google Scholar] [CrossRef] [PubMed]
- Diao, X.; Li, W.; Yu, J.; Wang, X.; Zhang, X.; Yang, Y.; An, F.; Liu, Z.; Zhang, X. Carrier-free, water dispersible and highly luminescent dye nanoparticles for targeted cell imaging. Nanoscale 2012, 4, 5373–5377. [Google Scholar] [CrossRef] [PubMed]
- Stapleton, S.; Dunne, M.; Milosevic, M.; Tran, C.W.; Gold, M.J.; Vedadi, A.; McKee, T.; Ohashi, P.S.; Allen, C.; Jaffray, D.A. Radiation and heat improve the delivery and efficacy of nanotherapeutics by modulating intra-tumoral fluid dynamics. ACS Nano 2018. [Google Scholar] [CrossRef] [PubMed]
Trade Name | Nanotechnology Platform | Cancer Type | Status |
---|---|---|---|
Doxil | Liposome | Ovarian cancer, HIV-related Kaposi sarcoma and multiple myeloma | Approved by the U.S. Food and Drug Administration (FDA) |
Genexol-PM | Micelle | Breast cancer and non-small-cell lung cancer | Approved in Korea |
Abraxane | Albumin NP | Lung, breast and pancreatic cancer | Approved by FDA |
CRLX-101 | Polymeric NP | Metastatic renal-cell carcinoma, non-small-cell lung cancer and recurrent tubal, ovarian, or peritoneal cancer | Phase II |
CYT-6091 | Colloidal gold NP | Advanced solid tumors | Phase I |
Kadcyla | Antibody-drug conjugate | HER-2 positive breast cancer | Approved by FDA |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, Y.; Yang, P.; Zhao, X.; Gao, D.; Sun, N.; Tian, Z.; Ma, T.; Yang, Z. Multifunctional Cargo-Free Nanomedicine for Cancer Therapy. Int. J. Mol. Sci. 2018, 19, 2963. https://doi.org/10.3390/ijms19102963
Wang Y, Yang P, Zhao X, Gao D, Sun N, Tian Z, Ma T, Yang Z. Multifunctional Cargo-Free Nanomedicine for Cancer Therapy. International Journal of Molecular Sciences. 2018; 19(10):2963. https://doi.org/10.3390/ijms19102963
Chicago/Turabian StyleWang, Ying, Pengfei Yang, Xinrui Zhao, Di Gao, Na Sun, Zhongmin Tian, Tianyou Ma, and Zhe Yang. 2018. "Multifunctional Cargo-Free Nanomedicine for Cancer Therapy" International Journal of Molecular Sciences 19, no. 10: 2963. https://doi.org/10.3390/ijms19102963